ID   1383D2
AC   CVCL_UP38
SY   HPS1005
DR   RCB; HPS1005
DR   Wikidata; Q93298761
RX   Patent=US20200407693;
RX   PubMed=28453617;
RX   PubMed=30853558;
CC   From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan.
CC   Population: Asian.
CC   HLA typing: A*02:07,32:01; B*15:02,51:01; C*08:01;14:02; DQA1*03:03,06:01; DQB1*03:01,03:02; DRB1*04:05,12:01 (PubMed=30853558).
CC   Omics: Genome sequenced.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_UP39 ! 1383D6
SX   Male
AG   36Y
CA   Induced pluripotent stem cell
DT   Created: 25-02-19; Last updated: 29-06-23; Version: 7
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=28453617; DOI=10.1093/biolre/iox038;
RA   Yokobayashi S., Okita K., Nakagawa M., Nakamura T., Yabuta Y.,
RA   Yamamoto T., Saitou M.;
RT   "Clonal variation of human induced pluripotent stem cells for
RT   induction into the germ cell fate.";
RL   Biol. Reprod. 96:1154-1166(2017).
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//